EYEG - EyeGate Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.2360
-0.0084 (-3.44%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.2444
Open0.2443
Bid0.2200 x 2200
Ask0.2862 x 3000
Day's Range0.2330 - 0.2444
52 Week Range0.2100 - 0.8600
Volume275,509
Avg. Volume524,450
Market Cap10.756M
Beta (3Y Monthly)2.15
PE Ratio (TTM)N/A
EPS (TTM)-0.1830
Earnings DateFeb 28, 2019 - Mar 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • Zacks Small Cap Research10 days ago

    EYEG: FDA Approves IDE. We Like Chances of Success of Upcoming OBG-PRK Pivotal Study

    By Brian Marckx, CFA NASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT FDA Approves IDE for OBG-PRK Pivotal Study, Topline Results Expected Later This Year… The major recent news on the operating front was ...

  • ACCESSWIRE12 days ago

    EyeGate Receives Approval from FDA to Initiate PRK Pivotal Study

    WALTHAM, MA / ACCESSWIRE / June 3, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company") announced today it has received approval from the U.S. Food and Drug Administration ("FDA") to initiate its photorefractive keratectomy ("PRK") pivotal study. The FDA has determined that EyeGate provided sufficient data to support initiation of the clinical study and has requested that EyeGate make some modifications to the patient informed consent document prior to enrollment. Stephen From, CEO of EyeGate, said, "We are extremely pleased with the feedback received from the FDA regarding the design of our PRK pivotal study and plan to begin enrollment as soon as possible.

  • ACCESSWIRElast month

    EyeGate Pharma Receives Positive Nasdaq Listing Determination

    WALTHAM, MA / ACCESSWIRE / May 14, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company") today announced that the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for the continued listing of its securities on The Nasdaq Capital Market ("Nasdaq"). The Company's continued listing on Nasdaq is subject to the Company evidencing a closing bid price of at least $1.00 per share for a minimum of ten consecutive trading days on or before September 16, 2019, which period constitutes the full extent of the Panel's discretion in this matter. EyeGate's OBG platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid ("CMHA-S"), a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface.

  • ACCESSWIRElast month

    EyeGate Pharma Reports First Quarter 2019 Financial Results and Provides Business Update

    WALTHAM, MA / ACCESSWIRE / May 8, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company") today announced financial results for the quarter ended March 31, 2019 and provided an update on recent corporate and operational activities. Stephen From, EyeGate's Chief Executive Officer, said, "During the first quarter of 2019, we continued to execute on our strategic initiatives, successfully confirming our path to a de novo filing for our lead product, Ocular Bandage Gel ("OBG"). Meeting held with the U.S. Food and Drug Administration ("FDA") on March 20, 2019 confirming the Company's path to a de novo filing for its OBG product for the indication of PRK surgery.

  • Zacks Small Cap Researchlast month

    EYEG: EYEG Submits IDE to FDA Seeking Approval to Commence Pivotal PRK Study

    This morning EyeGate (EYEG) announced that they submitted an Investigational Device Exemption (IDE) application to the FDA seeking approval to commence a pivotal study for OBG in PRK. FDA turnaround is anticipated in approximately 30 days. EYEG notes that while they wait for the U.S. regulatory agency’s answer, they will continue with the initiation of the planned study which, if successful, is expected to be used as primary support for a De Novo filing.

  • ACCESSWIRElast month

    EyeGate Files IDE with FDA for PRK Pivotal Study

    WALTHAM, MA / ACCESSWIRE / May 2, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) (''EyeGate'' or ''the Company'') announced today it has successfully submitted the Investigational Device Exemption (''IDE'') to the U.S. Food and Drug Administration (''FDA") regarding its photorefractive keratectomy (''PRK'') pivotal study. The review process takes 30 days, at which point the FDA will allow the Company to initiate enrollment or will provide comments to be addressed. Stephen From, CEO of EyeGate, said, ''Following the strength of our data in the PRK pilot study, the FDA recommended that we are ready to commence a pivotal study, which if successful, will allow us to file a de novo submission.

  • Zacks Small Cap Research3 months ago

    EYEG: Our Take On EYEG Moving Towards OBG-PRK Pivotal Study

    EyeGate (EYEG) announced financial results for their fourth quarter ending December 31st. For the full year, revenue was $1.7M, all of which relates to recognition of milestones from the EGP-437 development agreements with Bausch Health Companies (BHC). In the 10-K, EYEG discloses that they received a notice of termination from BHC on December 14th notifying them that BHC is voluntarily terminating these agreements effective March 14, 2019.

  • ACCESSWIRE3 months ago

    EyeGate Confirms Path to De Novo Filing with FDA

    WALTHAM, MA / ACCESSWIRE / March 26, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company") has met with the U.S. Food and Drug Administration ("FDA") regarding its Ocular Bandage Gel ("OBG") product and has confirmed its path to a de novo filing. The FDA has agreed that based on the strength of data from the photorefractive keratectomy ("PRK") pilot study, EyeGate is ready to move forward with a pivotal study, which will allow for a de novo filing. The Company plans to file the Investigational Device Exemption ("IDE") for initiation of the study in Q2 2019 and to complete the study in Q3 2019 with the de novo being filed soon thereafter.

  • ACCESSWIRE3 months ago

    EyeGate Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Business Update

    WALTHAM, MA / ACCESSWIRE / March 1, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) (''EyeGate'' or ''the Company'') today announced financial results for the year ended December 31, 2018 and provided an update on recent corporate and operational activities. Stephen From, EyeGate's Chief Executive Officer, said, ''This year EyeGate reached critical turning points in the path toward regulatory filings for approval and commercialization enabling us to further execute our strategy moving into 2019. Mr. From continued, ''We also reported positive topline data in key OBG clinical studies for both indications, photorefractive keratectomy (''PRK'') surgery and punctate epitheliopathies (''PE'').

  • GlobeNewswire5 months ago

    EyeGate Pharmaceuticals to Present at BIO CEO & Investor Conference in New York City

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”) today announced that the Company will attend and present at the 21st BIO CEO & Investor Conference being held in New York, NY at the New York Marriott Marquis on February 11th & 12th, 2019. The Company will also host one-on-one meetings through BIO CEO & Investor conference, which is one of the largest, unbiased forums of institutional investors, industry analysts, and biotechnology executives. Conference attendees can request meetings through the One-on-One Partnering platform, while non-attendees can send meeting requests to Joe Green at Edison Advisors.

  • GlobeNewswire5 months ago

    EyeGate Pharmaceuticals Announces Meeting Date with FDA

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”) today confirmed that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on Wednesday, March 20th, 2019 to discuss EyeGate’s de novo application strategy for its Ocular Bandage Gel (OBG) product, which will cover the clinical plan, data to date, and potential submission timelines. EyeGate’s OBG platform, a unique cross-linked hyaluronic acid compound, has potentially broad applications in managing ocular surface damage due to a variety of conditions, ranging from punctate epitheliopathies (PE) commonly found in dry eye patients, to large epithelial defects like those that occur following photorefractive keratectomy (PRK). EyeGate’s OBG platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S), a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface.

  • Zacks Small Cap Research6 months ago

    EYEG: Is EyeGate Eyeing FDA Filings Following Positive OBG Data in Both PRK and PE?

    EyeGate (EYEG) announced Q3 financial results and provided a business update. To-date, EYEG has received $13.8M in upfront and milestones under the two agreements, including ~$300k in the most recent quarter. While the yoy decrease reflects a change in activity from the relatively large EGP-437 trials to the smaller OBG studies, the qoq increase is a result of continued progression of both OBG programs.

  • GlobeNewswire7 months ago

    Investor Expectations to Drive Momentum within Atomera, YogaWorks, Cellect Biotechnology, Eyegate Pharmaceuticals, Zealand Pharma A/S, and Polar Power — Discovering Underlying Factors of Influence

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE7 months ago

    Drug Sales Up, Biotech Stocks Down, Here's a Profit Opportunity

    HENDERSON, NV / ACCESSWIRE / November 14, 2018 / With the sharp declines in biotechnology stocks, with the iShares Nasdaq Biotechnology exchange traded fund (ETF) and SPDR S&P Biotech ETF recently down ...

  • ACCESSWIRE7 months ago

    Today’s Research Reports on Stocks to Watch: Viking Therapeutics and EyeGate Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Shares of EyeGate exploded on Tuesday on tremendous volume after reporting third quarter financial results. Shares of Viking Therapeutics were little changed ...

  • GlobeNewswire7 months ago

    EyeGate Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”) today announced financial results for the three-month period ended September 30, 2018 and provided an update on recent corporate and operational activities. Stephen From, EyeGate’s Chief Executive Officer, said, “The third quarter of 2018 was a transformative quarter for EyeGate, with the Company receiving FDA approval for two IDE submissions for our Ocular Bandage Gel ('OBG') product, as well as focusing our efforts toward the key clinical trials that support this innovative product.” Mr. From continued, “We are extremely pleased to have announced positive top-line data in each of our OBG studies for photorefractive keratectomy ('PRK') surgery and punctate epitheliopathies ('PE').

  • ACCESSWIRE7 months ago

    4 Healthcare Stocks Investors Are Watching In November

    Eighty-three percent of healthcare organizations responding to an American Telemedicine Association* poll said they are highly likely to invest in telehealth with operational efficiency and convenience in mind. Of the 171 healthcare executives participating in the annual ATA Executive Leadership Survey, 88% of those who are likely to purchase telehealth tools are planning to do so. "This executive leadership survey confirms undeniably today's leaders view telemedicine as a major driver in transforming healthcare," said Jonathan Linkous, CEO, American Telemedicine Association.

  • GlobeNewswire7 months ago

    EyeGate Pharma Announces Positive Results in Punctate Epitheliopathy Study

    EyeGate Pharmaceuticals, Inc. (EYEG) today announced top-line data from its study evaluating the potential of EyeGate’s Ocular Bandage Gel (OBG) to help clinicians better manage patients with punctate epitheliopathies (PE) due to pathologies such as dry eye. Randall J Olson, M.D., CEO and Chair of the Department of Ophthalmology and Visual Sciences of the John A. Moran Eye Center, University of Utah, SLC, said, “A product that achieves symptomology results as seen in this study is exactly what ophthalmologists want access to when treating patients. This controlled, masked study enrolled 30 subjects with punctate epitheliopathies (PE) due to pathologies such as dry eye.

  • GlobeNewswire7 months ago

    EyeGate Pharma Announces Positive Results in Second PRK Study

    EyeGate Pharmaceuticals, Inc. (EYEG) today announced top-line data from its study evaluating the potential of EyeGate’s Ocular Bandage Gel (OBG) to help clinicians better manage corneal epithelial defects in patients following photorefractive keratectomy (PRK) surgery, compared to current standard of care. Daniel S. Durrie, M.D., Founder, Durrie Vision in Overland Park, KS, said, “This is the first time I have seen a product heal an epithelial defect without a bandage contact lens. The PRK study enrolled 45 subjects undergoing a bilateral PRK procedure.

  • Zacks Small Cap Research9 months ago

    EYEG: Focus Is On OBG As U.S. Pilot Studies Fully Enrolled. Data Expected Q4. EGP-437 Ph3 AE Data Disappoints

    EyeGate (EYEG) reported Q2 2018 financial results and provided a business update. Through Q2, EYEG collected $13.5M from Valeant related to upfront payments and development milestones associated with the development agreements for EGP-437 in anterior uveitis and post-cataract surgery. In terms of how these payments are recognized on EYEG’s financial statements, as a reminder an updated FASB standard governing revenue-recognition for contracts with customers resulted in a $9.5M adjustment to EYEG’s deferred revenue balance (as of Jan 1, 2018) – this is solely an accounting adjustment with no cash effect.